公开(公告)号：US11944643B2

公开(公告)日：2024-04-02

申请号：US16498899

申请日：2018-03-30

Applicant: CELLECTIS SA

Inventor： Julianne Smith ,  Philippe Duchateau ,  Murielle Derrien

IPC: A61K35/17 ,  A61K31/365 ,  A61K39/395 ,  A61P35/02 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28

CPC classification number: A61K35/17 ,  A61K31/365 ,  A61K39/39558 ,  A61P35/02 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/2803 ,  C07K2317/34 ,  C07K2317/53 ,  C07K2317/622

Abstract: The present invention relates to an engineered immune cell endowed with CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene that is able to redirect immune cell specificity and reactivity toward selected tumor cells. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.

公开(公告)号：US11576317B2

公开(公告)日：2023-02-14

申请号：US17098210

申请日：2020-11-13

Applicant: CELLECTIS SA ,  MEDICAGO INC.

Inventor： Luc Mathis ,  Daniel F. Voytas ,  Jin Li ,  Feng Zhang ,  Thomas Stoddard ,  Marc-Andre D'Aoust

IPC: A01H1/06 ,  A01H6/82 ,  A01H5/12 ,  C12N15/82 ,  C12N15/01 ,  C12N9/22 ,  C12P21/00

Abstract: Materials and methods are provided for making plants (e.g., Nicotiana varieties) that are suitable for producing therapeutic polypeptides suitable for administration to humans and animals, particularly by making TAL effector endonuclease-induced mutations in genes encoding xylosyltransferases and fucosyltransferases.

公开(公告)号：US11555198B2

公开(公告)日：2023-01-17

申请号：US14439420

申请日：2013-10-31

Applicant: CELLECTIS SA ,  MEDICAGO INC.

Inventor： Luc Mathis ,  Daniel F. Voytas ,  Jin Li ,  Feng Zhang ,  Thomas Stoddard ,  Marc-Andre D'Aoust

IPC: A01H1/06 ,  C12N15/82 ,  C12N15/01 ,  C12N9/22 ,  C12P21/00

Abstract: Materials and methods are provided for making plants (e.g., Nicotiana varieties) that are suitable for producing therapeutic polypeptides suitable for administration to humans and animals, particularly by making TAL effector endonuclease-induced mutations in genes encoding xylosyltransferases and fucosyltransferases.

公开(公告)号：US20210100839A1

公开(公告)日：2021-04-08

申请号：US16498276

申请日：2018-03-30

Applicant: CELLECTIS SA

Inventor： Cecile Schiffer-Mannioui ,  Philippe Duchateau ,  Anne-Sophie Gautron

IPC: A61K35/17 ,  C07K16/28 ,  C07K14/725 ,  C07K14/705

Abstract: The present invention relates to new CD22 Chimeric Antigen Receptors (CD22 CAR), an engineered immune cell endowed with said new CD22 CAR and comprising at least inactivated TRAC gene for use in therapy. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.

公开(公告)号：US20150247123A1

公开(公告)日：2015-09-03

申请号：US14425136

申请日：2013-09-03

Applicant: Novo Nordisk A/S ,  Cellectis SA

Inventor： Jenny Ekberg ,  Mattias Hansson ,  Ulrik Doehn ,  Katja Hess ,  Nina Funa

IPC: C12N5/071

CPC classification number: C12N5/0676 ,  C12N5/0678 ,  C12N2501/115 ,  C12N2501/117 ,  C12N2501/119 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/385 ,  C12N2501/41 ,  C12N2501/415 ,  C12N2501/60 ,  C12N2501/727 ,  C12N2501/999 ,  C12N2503/02 ,  C12N2506/02 ,  C12N2506/45

Abstract: A method of producing pancreatic cells or pancreatic cell precursors expressing at least 5% PDX1/NKX6.1 double positive, comprising exposing definitive endoderm cells to an effective amount of one or more small molecules, to differentiate the human definitive endoderm cells into the pancreatic cells or pancreatic cell precursors. The present invention also relates to pancreatic endoderm cells produced by said methods and uses of said pancreatic endoderm cells.

Abstract translation: 产生表达至少5％的PDX1 / NKX6.1双阳性的胰腺细胞或胰腺细胞前体的方法，包括将确定的内胚层细胞暴露于有效量的一种或多种小分子，以将人类确定的内胚层细胞分化成胰细胞 或胰腺细胞前体。 本发明还涉及通过所述方法产生的胰腺内胚层细胞和所述胰腺内胚层细胞的用途。

公开(公告)号：US20140120578A1

公开(公告)日：2014-05-01

申请号：US14068731

申请日：2013-10-31

Applicant: Medicago Inc. ,  Cellectis SA

Inventor： Luc Mathis ,  Daniel F. Voytas ,  Jin Li ,  Feng Zhang ,  Thomas Stoddard ,  Marc-André D'Aoust

IPC: C12N15/82 ,  C12N15/01 ,  C12P21/00

Abstract: Materials and Methods are provided for making plants (e.g., Nicotiana varieties) that are suitable for producing therapeutic polypeptides suitable for administration to humans and animals, particularly by making TAL effector endonuclease-induced mutations in genes encoding xylosyltransferases and fucosyltransferases.

Abstract translation: 提供材料和方法用于制备适于产生适于施用于人和动物的治疗性多肽的植物（例如烟草属），特别是通过在编码木糖基转移酶和岩藻糖基转移酶的基因中产生TAL效应子内切核酸酶诱导的突变。